tiprankstipranks
Advertisement
Advertisement
Aquestive Therapeutics options imply 7.1% move in share price post-earnings
PremiumThe FlyAquestive Therapeutics options imply 7.1% move in share price post-earnings
11d ago
AQST Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
AQST Upcoming Earnings Report: What to Expect?
14d ago
Aquestive Therapeutics assumed with an Outperform at Oppenheimer
Premium
The Fly
Aquestive Therapeutics assumed with an Outperform at Oppenheimer
1M ago
Aquestive Therapeutics Announces Key Legal Leadership Transition
PremiumCompany AnnouncementsAquestive Therapeutics Announces Key Legal Leadership Transition
2M ago
Aquestive chief legal officer, chief compliance officer Lori Braender steps down
Premium
The Fly
Aquestive chief legal officer, chief compliance officer Lori Braender steps down
2M ago
Aquestive Therapeutics Faces Investor Lawsuit Over Alleged FDA Approval Misrepresentations for Anaphylm
Premium
Class Action
Aquestive Therapeutics Faces Investor Lawsuit Over Alleged FDA Approval Misrepresentations for Anaphylm
2M ago
Aquestive Therapeutics Amends RTW Deal, Strengthens Financing Outlook
PremiumCompany AnnouncementsAquestive Therapeutics Amends RTW Deal, Strengthens Financing Outlook
3M ago
Aquestive Therapeutics reports Q4 adjusted EPS (15c), consensus (12c)
Premium
The Fly
Aquestive Therapeutics reports Q4 adjusted EPS (15c), consensus (12c)
3M ago
Aquestive Therapeutics sees FY26 revenue $46M-$50M, consensus $47.52M
Premium
The Fly
Aquestive Therapeutics sees FY26 revenue $46M-$50M, consensus $47.52M
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100